ImCheck Therapeutics Named to French Tech 120 for Sixth Consecutive Year
| Leadership & Corporate
Marseille, June 4, 2025 – ImCheck Therapeutics today announced its selection to the prestigious French Tech 120…
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
| Science & Medicine
ImCheck Therapeutics today announced the publication of its abstract for an upcoming oral presentation at the 2025 ASCO
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
| Science & Medicine
Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeuticsannounced today an oral…
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
| Science & Medicine
Date: Monday, April 28, 2025
Time: 9:00 am- 12:00 pm EST
Location: Poster Section 49 / Poster Board Number: 3
Replay of the Leukemia & Lymphoma Society's TAP event: Dr. Stephan Braun, our CMO, highlights ICT01 data presented at ASH 2024
| Science & Medicine
If you missed the ImCheck poster presentation at ASH 2024, you can watch Dr. Stephan Braun, our Chief Medical Officer,…
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Meeting Annual Meeting
| Science & Medicine
ImCheck Therapeutics announced today it will present positive interim results from its ongoing open-label, randomized…
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
| Science & Medicine
ImCheck Therapeutics announced today that updated data from its ongoing Phase I/II study EVICTION will be presented in…
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
| Science & Medicine
ICT01, a humanized anti-butyrophilin 3A monoclonal antibody designed to selectively activate Vγ9Vδ2 T cells, has shown…
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
| Financial & Business
ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and…
ImCheck Appoints Stephan Braun as Chief Medical Officer
| Leadership & Corporate
Dr. Braun brings over 30 years of drug development experience gained from an extensive career in both the…
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
| Science & Medicine
Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in…
ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation
| Leadership & Corporate
ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech…
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
| Science & Medicine
Interim data from EVICTION-2 study confirms safety and tolerability profile and broad anti-tumor immune response…
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
| Science & Medicine
ImCheck Therapeutics today announced that it will present updated data from its Phase I/IIa clinical trial…
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
| Science & Medicine
Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and…
ImCheck selected as laureate of the new French Tech 2030 program
| Leadership & Corporate
ImCheck is one of 5 therapeutic biotech companies and 25 healthcare start-ups/scale-ups among the 125 companies…
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
| Science & Medicine
ICT01 in combination with low dose IL-2 safely induced substantial γ9δ2 T cell expansion across multiple dosing…
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
| Leadership & Corporate
ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of…
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
| Science & Medicine
ImCheck Therapeutics today announced that it will present data from its Phase I/IIa clinical trial EVICTION-2 in a…
ImCheck Therapeutics is proud to be part of the FT120 for the fourth year in a row!
| Leadership & Corporate
The FT120 aims to support the growth of technology leaders and innovative companies that contribute to France's…